Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India

• Published in: Indian journal of hematology & blood transfusion 2023-10, Vol.39 (4), p.624-629
• Main Authors: Choraria, Nirmalkumar, Rangarajan, Savita, John, M. Joseph, Apte, Shashikant, Gupta, Pritam, Pai, Seema, Chand, Rohit, Parvatini, Shyam, Ramakanth, G. S. H., Rupon, Jeremy, Chhabra, Amit, Muley, Hitesh Bhaskarrao, Simoneau, Damien
• Format: Article
• Language: English
• Subjects: Blood Transfusion Medicine; Blood transfusions; Disease management; Disease prevention; Hematology; Hemophilia; Hemorrhage; Human Genetics; Medicine; Medicine & Public Health; Oncology; Original; Original Article
• ISSN: 0971-4502; 0974-0449; 0974-0449; 0971-4502
• DOI: 10.1007/s12288-022-01587-1

Purpose Hemophilia A is an X-linked congenital disorder, characterized by factor VIII (FVIII) deficiency. Globally, India has the highest population of patients with hemophilia, and there is a clear unmet need for appropriate and effective treatment for this patient population. This multicenter, open-label, post-approval study evaluated the safety and efficacy of moroctocog alfa in patients with moderate or severe congenital hemophilia A in India. Methods Intravenous moroctocog alfa was administered 30 ± 5 IU/kg 3 times weekly for bleeding prophylaxis, according to the local product document. Participants were treated for up to 8 weeks, with an up to 4-week screening period and a subsequent post-treatment, 28-day safety observation period. Patients continued in the study until at least 24 exposure days or a period of up to 8 weeks on moroctocog alfa. Results A total of 50 participants were enrolled, and 48 (85.7%) completed the study. No participants developed FVIII inhibitors during the study. The mean (SD) annualized bleeding rate during moroctocog alfa prophylaxis was 0.79 (2.0) with a median (range) of 0.00 (0.0, 6.8). The mean (SD) annualized total factor consumption (TFC) per participant was 287,432 (93,866) IU; the mean (SD) annualized TFC by weight per participant was 4176 (858) IU/kg. Moroctocog alfa was well tolerated with no reported treatment-emergent adverse event-related dose reductions, discontinuations, or serious adverse events. Conclusion Moroctocog alfa was safe, effective, and well tolerated in Indian participants with congenital moderate to severe hemophilia A. No participant developed FVIII inhibitors during the study.